Otsuka Pharmaceutical

Otsuka's kidney disease drug halves UPCR levels in ph. 3 study

Otsuka has shared data behind its kidney disease drug’s win, showing the monoclonal antibody halved patients’ urine protein-to-creatinine ratio levels.

James Waldron Jun 6, 2025 6:26am

Otsuka's Taiho pays $400M to buy Swiss ADC partner

Mar 17, 2025 8:10am

Otsuka's kidney disease drug improves UPCR levels in ph. 3 trial

Oct 22, 2024 10:38am

MA strategy deal block push come together form

Otsuka pays $800M for Jnana and its clinical-stage PKU drug

Aug 1, 2024 5:55am

Otsuka pays Ionis $65M for European rights to rare disease drug

Dec 19, 2023 10:18am

Otsuka eye disease strategy takes Shape with $1.5B biobucks deal

Sep 8, 2023 8:45am